DITTO Daily is a technology company.
DITTO Daily has raised $2.0M across 1 funding round.
DITTO Daily has raised $2.0M in total across 1 funding round.
DITTO Daily has raised $2.0M in total across 1 funding round.
DITTO Daily's investors include Eka Ventures, Pink Salt Ventures, Speedinvest, Vala Capital.
DITTO Daily is a UK-based health tech startup founded in 2024 that develops science-formulated supplements targeting menstrual cycle symptoms like PMS, PMDD, cramps, mood swings, bloating, and fatigue.[1][2][3][4][5] Its flagship product, the Cycle Supplement, serves women and people experiencing hormonal issues (including those with PCOS, endometriosis, perimenopause, or using hormonal contraception) by providing proactive, daily nutritional support through 10 clinically backed ingredients delivered via innovative "beadlet-in-oil" biotechnology for optimal absorption.[1][2][3][4][5] The company bridges the gap between menstrual health research and practical solutions, with early clinical trials showing an 88% reduction in symptom severity, rapid online community growth to over 116,000 Instagram and TikTok followers, and £1.35 million in pre-seed funding raised in 2025 led by Eka Ventures.[1][2][5]
This funding fuels product expansion, additional clinical trials, and market scaling, demonstrating strong growth momentum just months after launch in the UK.[1][2]
DITTO Daily was incorporated in 2024 as DITTO DAILY LTD and founded by nutrition scientist Alice van der Schoot, who specializes in evidence-based nutrition, lab work, and clinical trials.[1][4][5][6] She leads a team of female scientists and healthcare experts, including Dr. Tosin Sotubo-Ajayi (women's health GP with NHS experience) and advisers like Dr. Asha Malik (biomedical scientist).[3][4][5]
The idea emerged from a recognized disconnect between advanced menstrual health science and outdated, ineffective alternatives, prompting Alice to translate clinical research into accessible products.[1][2] Early traction came swiftly: launched four months before mid-2025 funding, the Cycle Supplement achieved excellent user uptake, an 88% symptom reduction in its first clinical trial, and a robust social media community.[1][5]
DITTO Daily rides the surging wave of women's health tech (FemTech), shifting from fertility-focused, reactive solutions to full-cycle, preventative hormonal care backed by science—a market pivot driven by rising demand for evidence-based wellness amid growing awareness of conditions like PMS and PMDD affecting billions.[1][2][3] Timing aligns with post-pandemic emphasis on personalized health, clinical rigor in supplements, and investor interest in underserved women's health, as seen in its quick £1.35M pre-seed from Eka Ventures.[1][2]
It influences the ecosystem by elevating standards: prioritizing biotech delivery, trial validation, and transparency over anecdotal claims, inspiring peers like Fairhaven Health and fostering a move toward holistic, lifecycle-oriented products that align research with real needs.[3]
With fresh funding and planned trials, DITTO Daily is poised to expand its product line, enter new channels, and solidify as a leader in science-driven menstrual health.[1][2] Trends like AI-personalized nutrition, global FemTech growth, and regulatory pushes for supplement efficacy will shape its path, potentially amplifying impact as clinical data accumulates.
Its influence may evolve from niche innovator to mainstream staple, empowering women through biotech that turns research into relief—echoing its founding mission to redefine menstrual care.
DITTO Daily has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $2.0M Seed | Eka Ventures, Pink Salt Ventures, Speedinvest, Vala Capital |